Methods of using PAF-antagonistic diazepines

Claim 1

A method of treating an individual having a disorder responsive to PAF-antagonist activity, which method comprises treating said individual with a therapeutically effective amount of a compound of formulae ##STR58## wherein A is an anellated ring of formula ##STR59## B is an anellated ring of formula ##STR60## R 1 and R 2 , are each independently hydrogen, a C 1 -C 8 straight-chained or branched alkyl, alkenyl or alkynyl optionally mono- or polysubstituted by halogen, hydroxy, alkoxy, alkylmercapto, amino, alkylamino, dialkylamino, alkylcarbonyl, alkyloxycarbonyl or an acid amide group; cycloalkyl; a saturated carbocyclic or heterocyclic ring condensed on, which may contain oxygen, sulphur or nitrogen as a heteroatom while the nitrogen-containing ring can carry an alkyl group at the nitrogen atom; halogen, trifluoromethyl, nitro, cyano, optionally substituted amino, alkylmercapto, alkylcarbonyl, alkoxy, alkyloxycarbonyl or an acid amide group; R 3 , R 4 R 5 and Z are each independently hydrogen, a C 1 -C 8 straight-chained or branched alkyl, alkenyl or alkynyl optionally mono- or polysubstituted by halogen, hydroxy, alkoxy, alkylmercapto, amino, alkylamino, dialkylamino, alkylcarbonyl, alkyloxycarbonyl, or an acid amide group; R 6 is phenyl, which can optionally be substituted, preferably in the 2 position, by methyl, methoxy, halogen, nitro or trifluoromethyl, or R 6 can be thienyl or α-pyridyl; Y is <CO, <CS or <CH 2 ; and non-toxic, pharmaceutically acceptable acid addition salts thereof.

Claim 2

A method of treating an individual having a disorder responsive to PAF-antagonist activity, which method comprises treating said individual with a therapeutically effective amount of a compound of formulae ##STR58## wherein A is an anellated ring of formula ##STR59## B is an anellated ring of formula ##STR60## R 1 and R 2 , are each independently hydrogen, a C 1 -C 8 straight-chained or branched alkyl, alkenyl or alkynyl optionally mono- or polysubstituted by halogen, hydroxy, alkoxy, alkylmercapto, amino, alkylamino, dialkylamino, alkylcarbonyl, alkyloxycarbonyl or an acid amide group; cycloalkyl; a saturated carbocyclic or heterocyclic ring condensed on, which may contain oxygen, sulphur or nitrogen as a heteroatom while the nitrogen-containing ring can carry an alkyl group at the nitrogen atom; halogen, trifluoromethyl, nitro, cyano, optionally substituted amino, alkylmercapto, alkylcarbonyl, alkoxy, alkyloxycarbonyl or an acid amide group; R 3 , R 4 R 5 and Z are each independently hydrogen, a C 1 -C 8 straight-chained or branched alkyl, alkenyl or alkynyl optionally mono- or polysubstituted by halogen, hydroxy, alkoxy, alkylmercapto, amino, alkylamino, dialkylamino, alkylcarbonyl, alkyloxycarbonyl, or an acid amide group; R 6 is phenyl, which can optionally be substituted, preferably in the 2 position, by methyl, methoxy, halogen, nitro or trifluoromethyl, or R 6 can be thienyl or α-pyridyl; Y is <CO, <CS or <CH 2 ; and non-toxic, pharmaceutically acceptable acid addition salts thereof.